SCHEMBL20181906

SCHEMBL20181906

COc1ncncc1-c1cn(C(/C(=C/Nc2ccccc2F)N=N)C2CC2)c2ncnc(N)c12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF2AK3 Q9NZJ5 5/20 0.34
CFTR P13569 3/20 0.34
EGFR P00533 3/20 0.33
SRC P12931 5/20 0.32
KDR P35968 2/20 0.32
TEK Q02763 2/20 0.32
LCK P06239 1/20 0.32
RIPK2 O43353 2/20 0.32
PDGFRB P09619 1/20 0.32
KIT P10721 1/20 0.32
FLT3 P36888 1/20 0.32
SIK1 P57059 1/20 0.32
RIPK4 P57078 1/20 0.32
DDR1 Q08345 1/20 0.32
RIPK1 Q13546 1/20 0.32
DSTYK Q6XUX3 1/20 0.32
RIPK3 Q9Y572 1/20 0.32
ERBB2 P04626 1/20 0.31
ERBB3 P21860 1/20 0.31
ERBB4 Q15303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20181916 0.87 CFTR (0.39) EIF2AK3CFTREGFRSRCKDR
SCHEMBL20182265 0.79 NTRK1 (0.36) EIF2AK3CFTREGFRKDRFLT3
SCHEMBL20182274 0.79 EIF2AK3 (0.40) EIF2AK3EGFRSRCKDRTEK
SCHEMBL20182194 0.78 EIF2AK3 (0.36) EIF2AK3CFTREGFRSRCKDR
SCHEMBL20182288 0.77 EIF2AK3 (0.39) EIF2AK3CFTREGFRSRCKDR
SCHEMBL20182224 0.77 EGFR (0.39) CFTREGFRSRCKDRTEK
SCHEMBL20182271 0.76 CFTR (0.35) EIF2AK3CFTREGFRSRCKDR
SCHEMBL20182191 0.76 ALK (0.34) EIF2AK3CFTREGFRSRCKDR
SCHEMBL20182227 0.74 EGFR (0.36) EIF2AK3EGFRSRCKDRTEK
SCHEMBL20182200 0.73 KDR (0.39) EIF2AK3SRCKDRTEKLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018094137-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) 2018-05-24 WO disclosed